{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:18:22Z","timestamp":1781111902959,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002663","name":"Northwestern Polytechnical University","doi-asserted-by":"publisher","award":["LO1304"],"award-info":[{"award-number":["LO1304"]}],"id":[{"id":"10.13039\/501100002663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["15-34613L"],"award-info":[{"award-number":["15-34613L"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["IGA MZ \u010cR NT 12218-4\/2011"],"award-info":[{"award-number":["IGA MZ \u010cR NT 12218-4\/2011"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["UP LF 2016-001"],"award-info":[{"award-number":["UP LF 2016-001"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ejps.2017.04.014","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T08:47:49Z","timestamp":1492678069000},"page":"335-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Novel sulphur-containing imatinib metabolites found by untargeted LC-HRMS analysis"],"prefix":"10.1016","volume":"104","author":[{"given":"Ivo","family":"Vrobel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3448-9073","authenticated-orcid":false,"given":"David","family":"Friedeck\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luk\u00e1\u0161","family":"Najdekr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate\u0159ina","family":"Mi\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radana","family":"Karl\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2017.04.014_bb0005","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00216-014-7682-2","article-title":"Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology","volume":"406","author":"Dahmane","year":"2014","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ejps.2017.04.014_bb0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1021\/tx049711r","article-title":"Metabolic activation of a 1,3-disubstituted piperazine derivative: evidence for a novel ring contraction to an imidazoline","volume":"18","author":"Doss","year":"2005","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejps.2017.04.014_bb0015","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2017.04.014_bb0020","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s10637-016-0342-y","article-title":"Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison","volume":"34","author":"Dubbelman","year":"2016","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejps.2017.04.014_bb0025","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1517\/17425255.2010.506873","article-title":"Metabolism considerations for kinase inhibitors in cancer treatment","volume":"6","author":"Duckett","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2017.04.014_bb0030","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","article-title":"Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates","volume":"165","author":"Filppula","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2017.04.014_bb0035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.chroma.2015.07.033","article-title":"Detailed study of imatinib metabolization using high-resolution mass spectrometry","volume":"1409","author":"Friedeck\u00fd","year":"2015","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ejps.2017.04.014_bb0040","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1124\/dmd.105.004283","article-title":"Metabolism and disposition of imatinib mesylate in healthy volunteers","volume":"33","author":"Gschwind","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.04.014_bb0045","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1124\/dmd.112.044636","article-title":"Metabolism of a G protein-coupled receptor modulator, including two major 1,2,4-oxadiazole ring-opened metabolites and a rearranged cysteine-piperazine adduct","volume":"40","author":"Gu","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.04.014_bb0050","first-page":"2011","article-title":"Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone","author":"Gupta","year":"2011","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.ejps.2017.04.014_bb0055","doi-asserted-by":"crossref","first-page":"22179","DOI":"10.1016\/S0021-9258(18)54551-8","article-title":"Intrahepatic conversion of a glutathione conjugate to its mercapturic acid: metabolism of 1-chloro-2,4-dinitrobenzene in isolated perfused rat and guinea pig livers","volume":"266","author":"Hinchman","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2017.04.014_bb0060","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1124\/dmd.111.043281","article-title":"Unique metabolic pathway of [(14)C]lenvatinib after oral administration to male cynomolgus monkey","volume":"40","author":"Inoue","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.04.014_bb0065","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1517\/17425255.2012.695347","article-title":"Role of reactive metabolites in the circulation in extrahepatic toxicity","volume":"8","author":"Irving","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2017.04.014_bb0070","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s13361-012-0354-6","article-title":"Simultaneous screening of glutathione and cyanide adducts using precursor ion and neutral loss scans-dependent product ion spectral acquisition and data mining tools","volume":"23","author":"Jian","year":"2012","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.ejps.2017.04.014_bb0075","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","article-title":"Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor","volume":"344","author":"Joensuu","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2017.04.014_bb0080","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s11095-012-0724-6","article-title":"Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction","volume":"29","author":"Kenny","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2017.04.014_bb0085","doi-asserted-by":"crossref","first-page":"11533","DOI":"10.1021\/ac503290j","article-title":"Untargeted profiling of tracer-derived metabolites using stable isotopic labeling and fast polarity-switching LC-ESI-HRMS","volume":"86","author":"Kluger","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejps.2017.04.014_bb0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/rcm.6758","article-title":"Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway","volume":"28","author":"Li","year":"2014","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.ejps.2017.04.014_bb0095","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/rcm.4023","article-title":"Characterization of imatinib metabolites in rat and human liver microsomes: differentiation of hydroxylation from N-oxidation by liquid chromatography\/atmospheric pressure chemical ionization mass spectrometry","volume":"23","author":"Ma","year":"2009","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.ejps.2017.04.014_bb0100","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/annonc\/mdq715","article-title":"Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients","volume":"22","author":"Marcolino","year":"2011","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ejps.2017.04.014_bb0105","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/jms.1002","article-title":"Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers","volume":"41","author":"Marull","year":"2006","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.ejps.2017.04.014_bb0110","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1476-5381.2010.00946.x","article-title":"Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes","volume":"161","author":"Nebot","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2017.04.014_bb0115","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6601152","article-title":"Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia","volume":"89","author":"O'Brien","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejps.2017.04.014_bb0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0021-9673(01)01111-6","article-title":"Identification and determination of glucuronides and their aglycones in Erigeron breviscapus by liquid chromatography-tandem mass spectrometry","volume":"928","author":"Qu","year":"2001","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ejps.2017.04.014_bb0125","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/jms.1369","article-title":"Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry","volume":"43","author":"Rochat","year":"2008","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.ejps.2017.04.014_bb0130","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate \u2014 a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2017.04.014_bb0135","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1471-2407-12-186","article-title":"Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)","volume":"12","author":"Seidel","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejps.2017.04.014_bb0140","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/17425255.2015.983075","article-title":"Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review","volume":"11","author":"Teo","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2017.04.014_bb0145","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1002\/cncr.29587","article-title":"Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"121","author":"Yilmaz","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ejps.2017.04.014_bb0150","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/jms.1390","article-title":"An algorithm for thorough background subtraction from high-resolution LC\/MS data: application for detection of glutathione-trapped reactive metabolites","volume":"43","author":"Zhang","year":"2008","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.ejps.2017.04.014_bb0155","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/jms.1610","article-title":"Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry","volume":"44","author":"Zhang","year":"2009","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.ejps.2017.04.014_bb0160","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s13361-016-1342-z","article-title":"Fragmentation of protonated N-(3-Aminophenyl)Benzamide and its derivatives in gas phase","volume":"27","author":"Zu","year":"2016","journal-title":"J. Am. Soc. Mass Spectrom."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717302087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717302087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T08:46:23Z","timestamp":1656924383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717302087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":32,"alternative-id":["S0928098717302087"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.04.014","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel sulphur-containing imatinib metabolites found by untargeted LC-HRMS analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}